StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report issued on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 0.9 %
Shares of PULM opened at $2.06 on Friday. The firm has a market cap of $7.52 million, a PE ratio of -0.70 and a beta of 0.99. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $2.75. The stock has a fifty day moving average price of $2.07 and a 200-day moving average price of $2.03.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%. The business had revenue of $1.55 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- Dividend Capture Strategy: What You Need to Know
- Palantir Cracks $50, Is There Still Time to Get on Board?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Insider Buying Signals Upside for These 3 Stocks
- What is the Nikkei 225 index?
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
